Cancer Treatment and Research Communications
Overview
Cancer Treatment and Research Communications is a scientific journal, published by Elsevier since 2016 in English. The journal's country of origin is United Kingdom and its primary focus area is oncology.
Details
Details
Abbr.
Cancer Treat Res Commun
Publisher
Elsevier
Start
2016
End
Continuing
e-ISSN
2468-2942
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 11752
23
SJR / Ranks: 5339
793
CiteScore / Ranks: 8566
3.00
Recent Articles
1.
Zheng S, Liu Y, Kinkopf P, Yalamanchili A, Strauss J, Donnelly E
Cancer Treat Res Commun
. 2025 Mar;
43:100890.
PMID: 40088596
Introduction: A small proportion of clinicopathologically low-risk endometrial cancer (EC) patients who omitted adjuvant radiotherapy (RT) may subsequently develop a local recurrence. Molecular profile for those clinically low-risk yet recurred...
2.
Ali S, Mehboob A, Arshad M, Mammadova K, Ahmad M
Cancer Treat Res Commun
. 2025 Mar;
43:100892.
PMID: 40088595
Cancer is the leading cause of death worldwide. Conventional cancer therapies, such as chemotherapy, radiation therapy, and immunotherapy often face certain limitations in treating cancer, such as toxicity, resistance, and...
3.
Laisaar T, Kallavus K, Poola A, Rappo M, Taur M, Makke V, et al.
Cancer Treat Res Commun
. 2025 Mar;
43:100889.
PMID: 40031097
Introduction: Lung cancer screening (LCS) is recommended by international societies, yet it is still debated how to efficiently enrol participants. The aim of this study was to evaluate systematic enrolment...
4.
Danzinger S, Spornberger V, Vietzen H, Tendl-Schulz K, Pfeiler G, Singer C, et al.
Cancer Treat Res Commun
. 2025 Mar;
43:100886.
PMID: 40031096
Introduction: Neoadjuvant chemotherapy (NACT) is an established form of therapy for early breast cancer (BC). The aim of our study was to analyze histopathological parameters before and after receiving NACT...
5.
Penteado M, Santos A, Graziano M, da Veiga G, Del Giglio A, Fonseca F, et al.
Cancer Treat Res Commun
. 2025 Mar;
43:100887.
PMID: 40023004
Purpose: Analysis of gene expression profiles in peripheral blood cells has been explored as an approach for early detection of breast cancer. Thus, we aimed to evaluate the diagnostic and...
6.
Chen B, Alder J
Cancer Treat Res Commun
. 2025 Mar;
43:100888.
PMID: 40023003
Glioblastomas comprise a significant percentage of malignant adult central nervous system tumor cases and patients typically do not survive longer than a year after diagnosis. There are few treatment options...
7.
Reinmuth N, Gessner C, Schichtl T, Schutte W, Hammerschmidt S, Schulz H, et al.
Cancer Treat Res Commun
. 2025 Mar;
43:100878.
PMID: 40023002
Background: Atezolizumab is the first approved PD-L1 inhibitor for patients with advanced non-small cell lung cancer (NSCLC) in Germany. This study aimed to assess effectiveness and safety of this checkpoint...
8.
Horkoss G, Khoury J, Halabi R, Kanbar A, Assaf S, Mina A, et al.
Cancer Treat Res Commun
. 2025 Feb;
43:100879.
PMID: 40009955
Introduction: Bladder cancer (BCa) is a very common urological cancer. Literature showed smoking as a main risk factor for BCa however patients may not be well-informed about the relation between...
9.
Naowaset P
Cancer Treat Res Commun
. 2025 Feb;
43:100885.
PMID: 39999730
Introduction: The incidence of DCIS (DCIS) constitutes 25 % of the newly identified breast cancers. Approximately 35 % of DCIS cases are detected in asymptomatic women during routine mammography screening....
10.
Mansour M, Kamer-Eldawla A, Malaeb R, Aboelhassan R, Nabawi D, Aziz M, et al.
Cancer Treat Res Commun
. 2025 Feb;
43:100881.
PMID: 39985914
Glioblastoma (GBM) is the most aggressive primary brain cancer, characterized by profound molecular and cellular heterogeneity, which contributes to its resistance to conventional therapies and poor prognosis. Despite multimodal treatments...